The antiprotozoal drug nitazoxanide improves experimental liver fibrosis in mice
Biochemical Pharmacology · 2024
DOI: 10.1016/j.bcp.2024.116205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2024. Verfasst von Kai-Xin Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, China Pharmaceutical University, Nanjing, People's Republic of China. Hauptthemen laut MEDLINE: Nitro Compounds, Thiazoles, Antiprotozoal Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Nitazoxanide is an FDA-approved antiprotozoal drug. Our previous studies find that nitazoxanide and its metabolite tizoxanide affect AMPK, STAT3, and Smad2/3 signals which are involved in the pathogenesis of liver fibrosis, therefore, in the present study, we examined the effect of nitazoxanide on experimental liver fibrosis and elucidated the potential mechanisms. The in vivo experiment results showed that oral nitazoxanide (75, 100 mg·kg-1) significantly improved CCl4- and bile duct ligation-induced liver fibrosis in mice. Oral nitazoxanide activated the inhibited AMPK and inhibited the activated STAT3 in liver tissues from liver fibrosis mice. The in vitro experiment results showed that nitazoxanide and its metabolite tizoxanide activated AMPK and inhibited STAT3 signals in LX-2 cells (human hepatic stellate cells). Nitazoxanide and tizoxanide inhibited cell proliferation and collagen I expression and secretion of LX-2 cells. Nitazoxanide and tizoxanide inhibited transforming growth factor-β1 (TGF-β1)- and IL-6-induced increases of cell proliferation, collagen I expression and secretion, inhibited TGF-β1- and IL-6-induced STAT3 and Smad2/3 activation in LX-2 cells. In mouse primary hepatic stellate cells, nitazoxanide and tizoxanide also activated AMPK, inhibited STAT3 and Smad2/3 activation, inhibited cell proliferation, collagen I expression and secretion. In conclusion, nitazoxanide inhibits liver fibrosis and the underlying mechanisms involve AMPK activation, and STAT3 and Smad2/3 inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, China Pharmaceutical University, Nanjing, People's Republic of China.
- Department of Pharmacology, China Pharmaceutical University, Nanjing, People's Republic of China. Electronic address: dongdeli@cpu.edu.cn.
- Department of Pharmacology, China Pharmaceutical University, Nanjing, People's Republic of China. Electronic address: sunzhijie@cpu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, K. X., Wang, Z. Y., Ying, Y. T., Wei, R. M., Dong, D. L., & Sun, Z. J. (2024). The antiprotozoal drug nitazoxanide improves experimental liver fibrosis in mice. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2024.116205
Vancouver
Liu KX, Wang ZY, Ying YT, Wei RM, Dong DL, Sun ZJ. The antiprotozoal drug nitazoxanide improves experimental liver fibrosis in mice. Biochemical Pharmacology. 2024. doi:10.1016/j.bcp.2024.116205
BibTeX
@article{Liu2024,
author = {Liu, Kai-Xin and Wang, Zeng-Yang and Ying, Ya-Ting and Wei, Rui-Miao and Dong, De-Li and Sun, Zhi-Jie},
title = {The antiprotozoal drug nitazoxanide improves experimental liver fibrosis in mice},
journal = {Biochemical Pharmacology},
year = {2024},
doi = {10.1016/j.bcp.2024.116205}
}
EUVIMED